Targeting specific immune cells to improve immunosuppression treatments
Albumin-Amended Antibody Drug Conjugate (A3DC) for Immunosuppression
This study is exploring a new way to help people with autoimmune diseases or those who have had organ transplants by using special treatments that can safely reduce certain immune cells, making it easier to manage their condition without causing long-term problems with their immune system.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-11119337 on NIH RePORTER |
What this research studies
This research focuses on developing a new approach to immunosuppression by targeting programmed death-1-positive (PD-1+) cells, which are crucial for maintaining immune responses in conditions like autoimmune diseases and organ transplants. The study aims to create antibody-drug conjugates that can effectively deplete these PD-1+ cells while preserving other immune cells, thus avoiding long-term immune deficiency. By engineering these targeted agents, the research seeks to enhance the effectiveness of immunosuppression without the adverse effects of current treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals undergoing treatment for autoimmune diseases or those requiring organ transplants.
Not a fit: Patients who do not have PD-1+ cell involvement in their condition may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunosuppression therapies that minimize side effects and improve patient outcomes.
How similar studies have performed: While similar approaches have shown promise in targeting immune cells, this specific method of using antibody-drug conjugates for PD-1+ cell depletion is relatively novel.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Chen, Mingnan — University of Utah
- Study coordinator: Chen, Mingnan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.